carcinoembryonic antigen


Also found in: Thesaurus, Medical, Encyclopedia, Wikipedia.
Related to carcinoembryonic antigen: alpha fetoprotein

car·ci·no·em·bry·on·ic antigen

 (kär′sə-nō-ĕm′brē-ŏn′ĭk)
n. Abbr. CEA
A glycoprotein present in fetal gastrointestinal tissue and in the cells or serum of adults having certain cancers. It is used clinically to monitor the effectiveness of a treatment, as for colorectal cancer.
Mentioned in ?
References in periodicals archive ?
Follow-up evaluations comprised carcinoembryonic antigen (CEA) assay, physical examination and history, routine blood tests, and visualization every three months for the first two years, every six months from the third to the fifth year, and annually thereafter.
The serum level of tumor marker including carcinoembryonic antigen and carbohydrate antigen 19-9 were 3.08 ng/mL and 0.6 U/mL, respectively.
Global carcinoembryonic antigen market segmented based on application of carcinoembryonic antigen: malignant condition and non-malignant condition.
Summary: Global carcinoembryonic antigen market segmented based on application of carcinoembryonic antigen: malignant condition and non-malignant condition.
Serum tumour marker carcinoembryonic antigen (CEA) also plays an important role in diagnosis and prognosis of lung cancer.
Conclusion: Tumour depth, lymph node metastasis, postoperative carcinoembryonic antigen levels, complete tumour response on histopathology were found to be responsible for metachronous liver metastases in rectal cancer patients following curative resection.
Immunohistochemical is favorable for antidiastole, especially prostate-specific antigen (PSA), carcinoembryonic antigen, and carcinoembryonic antigen 125.
Preoperative serum tumor markers, including carcinoembryonic antigen, CA 125, CA 19-9, and, in one case, squamous cell carcinoma antigen, have been within normal limits.
The authors based the model on a panel of selected circulating protein biomarkers (cancer antigen 125 [CA125], carcinoembryonic antigen [CEA], cytokeratin-19 fragment [CYFRA 21-1], and the precursor form of surfactant protein B [Pro-SFTPB]) and compared its performance to a traditional risk prediction model and current U.S.
C-stage in colon cancer: implications of carcinoembryonic antigen biomarker in staging, prognosis, and management.
Anti-extractable nuclear antigen, carcinoembryonic antigen, and alpha fetoprotein levels were unremarkable.
Perhaps the earliest markers to help in the clinical diagnosis were carcinoembryonic antigen (CEA) in colon carcinomas11 and prostate specific antigen (PSA)12 in prostate cancer.